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Background: Trivalent influenza vaccines (TIVs) offer substantial protection against matching B-strains,
however, protection against alternate-lineage B-strains may be enhanced by adding a second B-strain
in quadrivalent influenza vaccines (QIVs). In this Phase III, double-blind, multicentre, randomised study,
the immunogenicity and safety of subunit inactivated QIV versus TIV was assessed in adult (aged 18 to
60 years) and elderly (aged 61 years) subjects by analysing a combination of haemagglutinin inhibi-
tion (HI) and virus neutralisation (VN).
Methods: Subjects (n = 1980) were recruited off season (2015/2016) from 20 centres in five European
countries and randomised to receive either QIV (n = 1538), TIV with B-strain of the Victoria lineage
(n = 221) or TIV with B-strain of the Yamagata lineage (n = 221). The primary aim was to demonstrate
non-inferiority of QIV to TIV for immunogenicity against matched influenza strains based on post-
vaccination HI titres. Secondary aims were to show superiority of QIV to TIV for immunogenicity against
alternate-lineage B-strains and to characterise the immune response by reverse cumulative distribution
(RCD) curves of antibody titres and derived serological parameters for HI and VN. Reactogenicity and
occurrence of adverse events were assessed post-vaccination.
Results: QIV elicited a non-inferior immune response for matched strains (upper limit of 95% CI for HI
geometric mean ratios [GMRs] <1.5) and a superior response for alternate-lineage B-strains
(HI GMRs < 1; p < 0.0001) versus TIV. RCD curves demonstrated that post-vaccination HI and VN titres
were higher for QIV versus TIV for both alternate-lineage B-strains. Seroconversion rates and geometric
mean fold increases of the VN assay were consistent with the HI assay for all strains in QIV. Reporting
rates of local and systemic reactions were similar in both vaccine groups.
Conclusions: QIV was non-inferior in immunogenicity to TIV for matched strains and superior to the
alternate-lineage B-strains in TIV. Safety and tolerability profiles of QIV and TIV were comparable.
 2018 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Influenza is a respiratory infection caused by influenza viruses
that affects all ages, which can lead to serious complications in
high-risk individuals [1]. In temperate climates, seasonal influenza
epidemics occur during the winter months and are associated with
significant morbidity, mortality and economic burden [1–3].Influenza A/H1N1, A/H3N2 and B viruses are currently circulating
and can cause seasonal influenza outbreaks, with B viruses respon-
sible for a median of 17% of influenza cases between 2000 and
2015 in Europe [4]. The disease burden of both A and B viruses is
substantial, and B viruses have been estimated to be associated
with 25% of all influenza related mortality [3,5]. Two antigenically
distinct lineages of influenza B viruses (Victoria and Yamagata)
co-circulate globally with levels of each lineage varying in different
regions within the same influenza season [6–8]. Vaccination
remains the most effective method of preventing influenza; further
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lance and Response System recommends the composition of vacci-
nes based on the circulating influenza strains each influenza
season both in the northern and southern hemisphere [1].
Trivalent influenza vaccines (TIVs), such as Influvac (influenza
vaccine, surface antigen, inactivated; Abbott Biologicals B.V.,
Weesp, The Netherlands), are currently widely available and con-
tain two subtypes of influenza A (A/H1N1 and A/H3N2) and a
single-type influenza B-strain (either Victoria or Yamagata lin-
eage). TIVs have been shown to offer a high level of protection
against matched-lineage influenza B-strains with proven immuno-
genicity and safety [9–11]. However, as TIVs contain only one
B-strain, mismatch can occur between the recommended lineage
for TIV and the circulating B-strain [5]. Although TIVs provide some
cross-protection for alternate-lineage strains, quadrivalent influ-
enza vaccines (QIVs) containing B-strains from both the Victoria
and Yamagata lineages have been developed to prevent mismatch
[12]. Recent Phase III randomised clinical trials have demonstrated
superiority of QIVs versus TIVs for immunogenicity of alternate-
lineage B-strains and non-inferiority of QIVs versus TIVs for
immunogenicity of shared-lineage vaccine strains [13–17].
Traditionally, the haemagglutinin inhibition (HI) assay has been
the most important serological method used to investigate the
immunogenicity of influenza vaccines [18,19]. It measures the
antibodies against the haemagglutination antigen and correlates
with the ability of antibodies to inhibit virus infection of host cells
[19,20]. A serum HI titre of 40 is associated with a 50% reduction
in susceptibility to influenza. However, as the HI assay detects
antibodies solely against the influenza haemagglutinin protein,
testing additional serological antigens or serological parameters
may better assess vaccine effectiveness [20,21]. Consequently,
the European Medicines Agency (EMA) now recommends the use
of the virus neutralisation (VN) assay, which measures the levels
of functional systemic antibodies to inhibit the cytopathic effects
of the virus [20,22]. This assay provides valuable additional infor-
mation, because it is more sensitive for some influenza strains,
and detects additional virus antigens when compared with the HI
assay [20]. To our knowledge, our study is the first to date to report
VN as supplementary data to HI non-inferiority or superiority anal-
yses in a Phase III clinical trial of QIV versus TIV in accordance with
the new EMA guidelines on influenza vaccines [13–17].
In this Phase III, double-blind, multicentre, randomised study,
the immunogenicity and safety of Abbott’s candidate subunit inac-
tivated QIV versus Influvac, Abbott’s subunit inactivated TIV, was
assessed in adult (18 to 60 years of age) and elderly (61 years
of age) subjects. The primary aim was to demonstrate the non-
inferiority of QIV to TIV for shared-lineage influenza strains based
on the post-vaccination HI-titres. Secondary aims were to show the
superiority of QIV to TIV for alternate-lineage influenza B-strains
and to characterise the immune responses in detail by means of
reverse cumulative distribution (RCD) curves of antibody titres
and derived serological parameters for HI and VN. The safety pro-
file of QIV compared to that of TIV was assessed by analysing reac-
togenicity as well as the occurrence of unsolicited adverse events
(AEs).2. Materials and methods
2.1. Study design
This was a Phase III, randomised, double-blind, active-
controlled, three-arm, multicentre study (EudraCT number:
2014-001042-24). Eligible subjects were randomly assigned to
vaccination with QIV, TIV with B-strain of the Victoria lineage
(TIV(Vic)) or TIV with B-strain of the Yamagata lineage (TIV(Yam)).Immunogenicity and safety were assessed at Day 22 (21 days
post-vaccination) with a long-term safety follow-up period of 6
months. Written approval of the study was obtained from the rel-
evant Independent Ethics Committee/Institutional Review Board.
The study was conducted in compliance with Good Clinical Prac-
tice and all applicable laws and guidelines consistent with ethical
principles of the Declaration of Helsinki [23].
2.2. Study subjects
Study subjects were adults (18 to 60 years of age) and
elderly (61 years of age) stratified 1:1. The study included 20 cen-
tres in five European countries (Belgium, Germany, Hungary, Latvia
and Lithuania) and consisted of two visits and two phone contacts
per subject between May 2015 and January 2016. Male and female
subjects were included if they could give informed consent, were
18 years of age on the day of vaccination and were in stable
health. Exclusion criteria included: allergy to vaccine components;
history of Guillain Barré syndrome; treatment with any vaccine
within 4 weeks prior to the study vaccination or influenza vaccine
within the 6 months preceding enrolment; immunocompromisa-
tion; a history of known drug or alcohol abuse or any other charac-
teristic that, in the investigator’s opinion, prohibited the inclusion
of the subject into the study. Any medication that influenced the
immune system was not permitted 4 weeks prior to the start of,
or during, the study until the Day 22 assessment.
2.3. Randomisation and blinding
Subjects were randomly assigned to the three vaccine groups
through an interactive web response system (randomisation
scheme provided by Abbott Biologicals B.V.); randomisation was
by country and age group. Vaccines were supplied as pre-filled syr-
inges, and to achieve double-blindness, all syringes were identical
in appearance. All study investigators and subjects remained
blinded throughout the duration of the study; for emergency un-
blinding, an interactive web response system could be used.
2.4. Vaccines and vaccination schedule
Each subject received one 0.5 ml dose containing 15 mg of
haemagglutinin for each virus strain by intramuscular injection
(deltoid) using a 25 mm needle (QIV, 1095939-G54A; TIV(Vic),
1095937-G52; TIV(Yam), 1095938-G53). All study vaccines were
manufactured by Abbott Biologicals B.V. Blood samples were taken
at Day 1 (before vaccination) and at Day 22 (21 days post-
vaccination).
2.5. Immunogenicity endpoints
The immunogenicity endpoints were Day 22 post-vaccination
HI antibody titres and Day 22 post-vaccination VN antibody titres
against the four virus strains.
2.5.1. Primary immunogenicity analysis
The non-inferiority of QIV to TIV with respect to induced
immunogenicity against the shared strains was tested by compar-
ing the Day 22 HI geometric mean titres (GMTs) of the shared
strains between the QIV and TIV formulations in subjects 18
years of age (per-protocol sample [PPS]).
2.5.2. Secondary immunogenicity analysis
The superiority of QIV to TIV with respect to induced immuno-
genicity against the alternate-lineage B-strains was tested by com-
paring the Day 22 HI GMTs of the alternate-lineage B-strains
between QIV and TIV formulations in subjects 18 years of age.
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by analysing pre- and post-vaccination HI and VN GMTs, seropro-
tection rates (SPRs), seroconversion rates (SCRs) and geometric
mean fold increases (GMFIs) in HI and VN titres. SPRs were defined
as the proportion of subjects achieving an HI titre 40 (appropriate
VN titres to derive SPRs are currently unknown). SCRs for HI and
VN were both defined as becoming seropositive if seronegative at
enrolment, or a 4-fold rise in titre if seropositive at enrolment.
2.5.3. Safety endpoints
The safety endpoints were the frequency and severity of soli-
cited local and systemic reactions reported as per home diary for
a period of 7 days after vaccination. In addition, a general question
at the end of the 7-day reporting period was asked regarding over-
all inconvenience after the vaccination. Unsolicited AEs (both non-
serious and serious) were recorded up to the Day 22 visit, and only
serious unsolicited AEs (SAEs) and new chronic illnesses (NCIs)
were recorded between Day 22 and Day 183 (6 months).
2.5.4. Sample size determination and statistical analyses
The sample size was confirmed by scientific advice obtained
from an EU National Competent Authority to collect safety data
for approximately 1500 subjects vaccinated with QIV. Given this,
a sample size of 1540 subjects vaccinated with QIV and two times
220 subjects vaccinated with TIV secured an overall statistical
power of >95% to demonstrate the non inferiority of QIV to TIV
with respect to the immunogenicity against the shared strains.
Log-transformed HI titres were compared between the groups
by means of analysis of variance (ANOVA), with country and age
group as covariates. Non-inferiority of QIV to TIV could be con-
cluded if all four two-sided 95% confidence intervals (CIs) for the
geometric mean ratios (GMRs) would fall below the predefined
non-inferiority margin of 1.5. The non inferiority margin of 1.5
was set in accordance with current regulatory guidance [24]. The
PPS was used for the primary non-inferiority analysis, in accor-
dance with the International Conference on Harmonisation E9
guideline Statistical Principles for Clinical Trials [25].
Superiority of QIV over TIV (with regard to inducing higher
immune responses) was investigated using the ANOVA model
described above. Superiority could be concluded if the two-sided
95% CI fell below 1. Derived serological parameters and RCD curves
were summarised for each of the four strains in each of the three
formulations and each age cohort. The RCD plot is a graphical tool
to display the distribution of immunogenicity values and is useful
for visual comparisons of distributions between vaccine groups
[26]. The x-axis represents the immunogenicity values, the y-axis
the proportion of subjects having at least that immunogenicity
level. The curve begins at 100% and then descends from left to
right. If the RCD curve for one vaccine is above the curve for
another vaccine, then the vaccine with the highest curve induced
the greatest immune responses. If two RCD curves coincide it
demonstrates comparable immune responses.3. Results
3.1. Demographics and baseline characteristics
A total number of 1980 subjects were randomised to receive
QIV (n = 1538), TIV(Vic) (n = 221) or TIV(Yam) (n = 221) (Fig. 1). Over-
all, 11 subjects prematurely withdrew from the study; the reasons
were: withdrawal of consent (n = 4), AEs (n = 3), lost to follow-up
(n = 3), or administrative (n = 1). Subjects were predominantly
white (99.5%) and mean age at screening was 55.7 years
(SD ± 17.7 years) (Table 1). The proportion of male to female
subjects was 43.4–56.6%.3.2. Immunogenicity
3.2.1. Primary efficacy
For all four influenza strains in the PPS, the upper limit of the
95% CI for the adjusted HI GMR fell below the non-inferiority mar-
gin of 1.5, demonstrating non-inferiority of QIV versus TIV for
shared strains (Fig. 2a). The non-inferiority analysis was repeated
for the full analysis sample and the results were comparable (data
not shown).
3.2.2. Secondary efficacy
For both B-strain influenza lineages, the post-vaccination HI
GMT of the TIV group with the alternate B-strain lineage was less
than half that of the QIV group. The HI GMTs in the QIV group
for B/Victoria and B/Yamagata lineages were 153.1 and 101.9 ver-
sus 64.1 and 47.2 for the alternate lineages in the TIV groups,
which translated to an adjusted HI GMR of 0.41 and 0.45, respec-
tively (Fig. 2b, p < 0.0001 for both comparisons). The HI antibody
responses elicited by the B-strain antigens were, therefore, supe-
rior to the antibody responses elicited by cross-reactivity antigens
of the alternate-lineage B-strains.
In the QIV group, SPRs were 91.6% in adult subjects and
73.3% in elderly subjects for all four influenza strains (Supple-
mental Material Table 1). SCRs based on HI titres were 51.3% in
adult subjects and 39.3% in elderly subjects for all four influenza
strains. SCRs based on VN titres were in line with the HI titres, with
values of 42.5% in adult subjects and 34.1% in elderly subjects
for all four strains. GMFIs in HI titres varied between 6.3 and
11.4 in adult subjects versus 4.2 and 5.5 in elderly subjects. Across
all subjects, GMFIs in VN titres were in line with the HI titres,
although differences were less pronounced: between 3.1 and 5.4
in adult subjects versus 2.4 and 3.4 in elderly subjects. HI and
VN GMTs pre- and post-vaccination in adult and elderly subjects
are shown in Supplemental Material Table 2.
In all vaccine groups pre vaccination, the HI and VN RCD curves
were similar for each of the tested influenza strains, indicating a
lack of baseline serological bias between study groups (data not
shown). Post-vaccination, the proportion of subjects reaching
higher HI and VN titres increased. While the post-vaccination
RCD curves were similar for the shared-lineage influenza strains,
for the alternate-lineage B-strains, there was a shift in the TIV
RCD curves demonstrating that a lower proportion of subjects
achieved HI titres 10.0 and VN titres 28.3 versus QIV (Fig. 3).
3.3. Safety and tolerability
Local and systemic reaction profiles were comparable between
QIV and TIV 7 days post vaccination across all subjects; most reac-
tions were mild or moderate in severity and lasted for 1–3 days for
the majority of subjects. In adult subjects, reporting rates for sys-
temic reactions were generally low (<10%), except for headache
and fatigue (Fig. 4A). Headache was the most common systemic
reaction reported by 12.4% and 13.1% of adult subjects in the QIV
and TIV groups, respectively (Fig. 4A). Reporting rates of local reac-
tions were also generally low (<10%), except for vaccination-site
pain, which was reported by 24.9% and 18.5% of adult subjects in
the QIV and TIV groups, respectively (Fig. 4A). Reporting rates of
local and systemic reactions in elderly subjects followed a similar
profile to that of adult subjects, although overall reporting rates
were lower. The only local or systemic reaction occurring in >10%
of elderly subjects in either vaccine group was fatigue, which
was reported by 10.6% and 6.8% of subjects in the QIV and TIV
groups, respectively (Fig. 4B). The vast majority of subjects did
not experience any overall inconvenience during the 7 days after
vaccination and the frequency of overall inconvenience was similar
between the QIV and TIV groups (data not shown).
Fig. 1. Subject disposition (CONSORT flow diagram). AE, adverse event; QIV, quadrivalent influenza vaccine; TIV, trivalent influenza vaccine; Vic, Victoria lineage; Yam,
Yamagata lineage.
Table 1
Subject demographics at baseline.
Statistic QIV
(N = 1538)
TIV(Vic)
(N = 221)
TIV(Yam)
(N = 221)
All subjects
(N = 1980)
Age (years) Mean (SD) 55.9 (17.6) 55.4 (18.0) 55.0 (17.6) 55.7 (17.7)
Median 61.0 61.0 60.0 61.0
Min/Max 18/91 18/88 18/86 18/91
Age group
Adult subjects (18 to 60 years) n (%) 769 (50.0) 110 (49.8) 112 (50.7) 991 (50.1)
Elderly subjects (61 years) n (%) 769 (50.0) 111 (50.2) 109 (49.3) 989 (49.9)
Gender
Male n (%) 664 (43.2) 100 (45.2) 95 (43.0) 859 (43.4)
Female n (%) 874 (56.8) 121 (54.8) 126 (57.0) 1121 (56.6)
Race
White n (%) 1529 (99.4) 221 (100.0) 221 (100.0) 1971 (99.5)
Asian n (%) 3 (0.2) 0 0 3 (0.2)
Black or African American n (%) 3 (0.2) 0 0 3 (0.2)
Other n (%) 3 (0.2) 0 0 3 (0.2)
Max, maximum; Min, minimum; QIV, quadrivalent influenza vaccine; SD, standard deviation; TIV, trivalent influenza vaccine; Vic, Victoria lineage; Yam, Yamagata lineage.
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between the QIV and TIV groups; the vast majority of subjects
did not report any AEs up to the Day 22 visit (Table 2). The
frequency of adult subjects reporting at least one AE was 4.8%
and 3.6% in the QIV and TIV groups, respectively. Similarly, the fre-
quency of elderly subjects reporting at least one AE was 3.8% and2.7% in the respective QIV and TIV groups (Table 2). The most fre-
quent AEs were in the category of infections and infestations across
all subjects (data not shown). The proportion of subjects experi-
encing vaccine-related AEs was low (<1%) for both vaccine groups
across all subjects. Both QIV and TIV had favourable long-term
safety profiles (Day 22 to Day 183), with the incidence of both SAEs
Fig. 2. (A) Non-inferiority analysis of QIV versus TIV for the immunogenicity of shared influenza strains in subjects 18 years of age (per-protocol sample). Adjusted HI GMR
and 95% CI were calculated using ANOVA on the log-transformed titres at the Day 22 visit. The non-inferiority margin of 1.5 (dashed line) was pre-determined in accordance
with current regulatory guidance [24]. (B) Superiority analysis of QIV versus TIV for the immunogenicity of alternate-lineage influenza B-strains in subjects 18 years of age
(full analysis sample). Superiority was analysed using an ANOVAmodel for the log-transformed titres and superiority of QIV was demonstrated if the two-sided 95% CI for the
adjusted GMR fell below 1 (solid grey line). ***p < 0.0001 (two-sided ANOVA). aHI data for the two A-strains in TIV were pooled. ANOVA, analysis of variance; CI, confidence
interval; FDA, Food and Drug Administration; GMT, geometric mean titre; GMR, geometric mean ratio; HI, haemagglutinin inhibition; QIV, quadrivalent influenza vaccine;
TIV, trivalent influenza vaccine; Vic, Victoria lineage; Yam, Yamagata lineage.
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with a reasonable possibility for a causal relationship with the
study vaccine. Overall, the safety profile of QIV was similar to that
of TIV and both vaccine types were generally well tolerated.
4. Discussion
In this Phase III, randomised, double-blind clinical trial in adult
(18 to 60 years of age) and elderly (61 years of age) subjects,
the immune response, as defined by post-vaccination HI titres to
QIV, was non-inferior to that of TIV for shared influenza strains.
These data demonstrate that the presence of a second influenza
B-strain in QIV does not negatively affect immune response to
the other strains. Moreover, the immune response to QIV was
superior to cross-reactive titres against the alternate-strain lineage
in TIV, which is consistent with other Phase III trials comparinginactivated QIVs versus TIVs [13–17]. Collectively, these data indi-
cate that the addition of a second B-strain in QIV may enhance the
protective efficacy of influenza vaccines on occasions where mis-
match would occur between the recommended B-strain for TIV
and the one predominantly circulating. As influenza B is associated
with substantial mortality and economic burden, the use of QIVs
over TIVs may further reduce the burden of influenza [3,5]. In addi-
tion, modelling studies suggest that QIVs could be more cost-
effective than TIVs in protecting children and the elderly against
influenza, further suggesting a positive impact on healthcare for
QIVs [27].
In this study, the HI data showed a strong serological response
for each of the shared influenza strains in the QIV and TIV groups,
and the percentage of subjects in the QIV group achieving a serum
HI titre  40 (SPR) was high both for adult and elderly subjects.
Importantly, the HI immunogenicity data were supplemented with
Fig. 3. Reverse cumulative distribution curves of HI titres (A) and VN titres (B) in subjects 18 years of age pre- and post-vaccination with QIV or TIV for each of the four
strains. When the QIV and the TIV curves overlap, the two vaccines induced comparable immune responses. If the curve for QIV is above the curve for TIV, QIV induced the
higher immune response. HI, haemagglutinin inhibition; QIV, quadrivalent influenza vaccine; TIV, trivalent influenza vaccine; VN, virus neutralisation.
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Fig. 4. Local and systemic reactions 7 days after vaccination in (A) adult (18 to 60 years of age) and (B) elderly (61 years of age) subjects (safety sample). Data are
presented as percentage of subjects experiencing a vaccination reaction. ªThe safety data of the subjects vaccinated with TIV formulations were pooled. QIV, quadrivalent
influenza vaccine; TIV, trivalent influenza vaccine.
Table 2
Subjects with 1 AE during the immunisation phase (Days 1–22 post-vaccination) and the long-term safety follow-up (Days 22–183).
Adult subjects
(18 to 60 years)
Elderly subjects
(61 years)
QIV
(N = 768)
TIVa
(N = 222)
QIV
(N = 767)
TIVa
(N = 219)
Immunisation phase
Unsolicited AE, n (%) 37 (4.8) 8 (3.6) 29 (3.8) 6 (2.7)
SAE, n (%) 2 (0.3) 0 4 (0.5) 1 (0.5)
AE with possibility for a causal relationship, n (%) 4 (0.5) 2 (0.9) 6 (0.8) 2 (0.9)
AE leading to study termination, n (%) 0 0 0 0
Death, n (%) 0 0 0 0
Long-term safety follow-up
SAE, n (%) 10 (1.3) 4 (1.8) 30 (3.9) 9 (4.1)
NCI, n (%) 10 (1.3) 3 (1.4) 31 (4.0) 5 (2.3)
SAE/NCI with possibility for a causal relationship, n (%) 0 0 0 0
AE leading to study termination, n (%) 1 (0.1) 0 2 (0.3) 0
Death, n (%) 1 (0.1) 0 4 (0.5) 0
AE, adverse event; NCI, new chronic illness; QIV, quadrivalent influenza vaccine; SAE, serious adverse event; TIV, trivalent influenza vaccine.
a Safety data of the subjects vaccinated with TIV were pooled.
6036 S. van de Witte et al. / Vaccine 36 (2018) 6030–6038VN assay analyses, a combination that has not been reported in
other recent Phase III clinical trials of QIV versus TIV [13–17]. This
study demonstrated that the GMFIs and SCRs of the VN assay were
consistent with those of the HI assay, indicating the effectiveimmunogenicity of QIV and validating the use of VN testing for
future investigation into influenza vaccines. These data were con-
sistent with the results of a smaller Phase I/II single-centre,
single-blind study investigating QIV versus TIV [28] and a Phase
S. van de Witte et al. / Vaccine 36 (2018) 6030–6038 6037III trial that was not powered to assess non inferiority or superior-
ity of QIV responses versus TIV from HI analyses [29].
HI and VN assays have different strengths and limitations.
Whilst an HI titre of 40 is currently the only universal indicator
of a 50% reduction in the risk of influenza disease, HI titres only
correlate with the ability of antibodies to inhibit virus infection
of host cells [19,20]. In contrast, the VN assay measures the anti-
body titres needed to inhibit the cytopathic effects of the virus
and more closely mirrors the physiology of the influenza disease
process compared with the HI assay [20]. The VN assay is generally
thought to be more sensitive than the HI assay, but it is also more
expensive and time-consuming, and harder to standardise across
different laboratories [20]. Because of these strengths and limita-
tions, assessing both anti-HI and VN antibody responses may
enhance the overall accuracy of vaccine testing.
The recent EMA guidelines also recommend the reporting of
RCD curves, to provide valuable insight into the distribution of
antibody titres between study populations and vaccination groups
pre- and post-vaccination [22]. Importantly, the RCD data demon-
strated that pre vaccination titres were similarly distributed for
each of the tested influenza strains for all vaccine groups, indicat-
ing an absence of serological imbalances pre-vaccination with QIV
or TIV. For both alternate-lineage B-strains, post-vaccination HI
and VN titres were higher for QIV versus TIV, further validating
the addition of the extra B-strain in QIVs.
Overall, the results of this study demonstrate that the additional
B-strain in QIV did not compromise safety compared to TIV.
Reporting rates of unsolicited AEs were low and similar between
the vaccine groups up to Day 22 and none of the reported SAEs
or NCIs during the long-term follow-up period had a reasonable
possibility for a causal relationship with the study vaccine. Local
and systemic reactogenicity profiles were also similar between
vaccine groups; the majority of reactions were mild or moderate
in severity and lasted for 1–3 days. These data are consistent with
the results of a meta-analysis of five randomised clinical trials,
demonstrating that there was no significant difference between
QIV and TIV in terms of the frequency of aggregated local and sys-
temic AEs within 7 days post-vaccination [30].
Influvac subunit TIV has been used for over 30 years with a
well-established immunogenicity and safety profile [9]. In this
study, we demonstrated that the immunogenicity of the influenza
strains in QIV was non-inferior to the shared strains and superior
to the alternate-lineage B-strains in TIV. Furthermore, the safety
profiles of the two vaccine groups were comparable. Collectively,
these data support the use of Influvac QIV for seasonal vaccina-
tion in adult and elderly subjects, which may enhance the protec-
tion against influenza and decrease the burden associated with
influenza complications.Funding support
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